TrialInternational journal of molecular sciences2025

Investigation of the Relevance of CYP3A4 Inhibition on the Pharmacokinetics of the Novel P2X3 Antagonist Filapixant: Results of In Vitro Explorations and a Fixed-Sequence Clinical Trial with Itraconazole in Healthy Volunteers.

Klaus Francke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.